CALHM2

Across TCGA pan-cancer cohorts, CALHM2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CALHM2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CALHM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CALHM2 expression acts as an unfavorable survival marker.

LSCC, GBM, and LUAD are the cancer types where CALHM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.753	1.000	.003	21	view →
GBM	DFS	Median	All	0.268	0.445	.017	3	view →
LUAD	DFS	Median	All	0.900	0.982	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CALHM2–LSCC (DFS)

Open the LSCC breakdown →